{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"CBR of single agent pembrolizumab in subjects with refractory germ cell tumors (GCTs), determined by sum of complete responses, partial responses, and stable disease for at least 3 months using Immune Related Response Criteria (irRC).\n\nComplete Response(irPR): Disappearance of all lesions in two consecutive observations not less than 4 wk apart.\n\nPartial Response (irPR): decrease in tumor burden ≥50 %relative to baseline confirmed by a consecutive assessment at least 4 wk after first documentation.\n\nStable Disease (irSD): not meeting criteria for irCR or irPR, in absence of irPD.","groups":[{"description":"Pembrolizumab\n\nPembrolizumab: 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or after 52 weeks of therapy.","id":"OG000","title":"Experimental Arm"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"up to 18 weeks","title":"Clinical Benefit Rate (CBR)","type":"PRIMARY","unitOfMeasure":"percentage of participants w/ clinical b"}